Bionexus Gene Lab Corp. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Bionexus Gene Lab Corp. on July 20, 2023. The report details the effective date of a revised reverse stock split and amendments to the Company's Articles of Incorporation. The Company is incorporated in Wyoming with principal executive offices in Kuala Lumpur, Malaysia.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The report focuses exclusively on corporate governance and capital structure changes.
Material Changes
- Revised Reverse Stock Split: The Company amended its Articles of Incorporation to change the reverse stock split ratio from one-for-ten (10) to one-for-twelve (12).
- Effective Date: The Revised Reverse Stock Split became effective on July 20, 2023.
- Share Consolidation: Every twelve (12) outstanding shares of common stock were combined into one share of common stock.
- Fractional Shares: No fractional shares were issued. Fractional shares or odd lots (less than 100 shares) were rounded up to the nearest whole share or to 100 shares, respectively.
- Authorized Capital: The authorized share count remains unchanged at 300,000,000 shares of common stock and 30,000,000 shares of preferred stock.
- Security Identifier: The new CUSIP number following the split is 090628207.
Guidance, Outlook, and Risks
The filing contains no management commentary regarding future financial guidance, operational outlook, or specific risk factors. The document notes that the reverse stock split does not alter the par value of the common stock or modify voting rights. The full text of the Articles of Amendment is referenced as Exhibits 3.1 and 3.2.
Investor Verification Checklist
- Verify the new CUSIP number (090628207) with your brokerage to ensure proper account adjustment.
- Confirm the exact number of shares held post-split, noting the rounding up of fractional shares or odd lots.
- Review the Articles of Amendment (Exhibits 3.1 and 3.2) for any additional terms not summarized in the 8-K.
- Check for subsequent filings regarding the Company's financial status, as this 8-K contains no financial data.